Shigellosis is responsible for around 1 million deaths worldwide each year, and as yet there is no effective vaccine to present this disease. We intend to develop a new generation of shigella vaccines. This will be achieved by learning lessons from the limitations of current vaccine candidates, and extending our knowledge of pathogenesis and of the detailed structure of potential vaccine targets. We will then use novel methods to present and deliver antigens to the immune system , and identify the best vaccine candidates for subsequent clinical trials.
Funding SchemeCSC - Cost-sharing contracts